Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD [Phase 1]
Phase 1 trial assessing safety, tolerability, and pharmacokinetics of intravitreal pegcetacoplan (APL-2) for neovascular age-related macular…
-
CLINICAL_TRIALS trial_result · 2020-09-16Clinical Trial Update: Pegcetacoplan (APL-2) in Neovascular AMD [Phase 1, Phase 2]
Phase 1/2 trial of pegcetacoplan (APL-2) in neovascular age-related macular degeneration was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-09-02Clinical Trial Update: Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing monthly versus PRN ranibizumab in neovascular age-related macular degeneration has completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-08-03Clinical Trial Update: Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration [Phase 3]
A Phase 3 trial update assessing the safety of brolucizumab 6 mg in a prefilled syringe for neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-06-19Clinical Trial Update: Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating dorzolamide-timolol in combination with anti-VEGF injections for neovascular/wet age-related mac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-06-09FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BEOVU (brolucizumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD [Phase 3]
Phase 3 trial update for brolucizumab 6 mg in neovascular age-related macular degeneration has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 [Phase 3]
Completed Phase 3 trial (Study 1) comparing RTH258 (brolucizumab) with aflibercept in neovascular age-related macular degeneration, with eff…
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 [Phase 3]
A Phase 3 study comparing RTH258 (brolucizumab) to aflibercept in neovascular age-related macular degeneration focuses on efficacy and safet…
-
FDA approval · 2019-10-07FDA Approved: BEOVU — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved BEOVU (brolucizumab) under an original application from Novartis Pharmaceuticals Corporation for the treatment of neovascul…
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. [Phase 4]
Phase 4 trial evaluating the usefulness of a treat-and-extend regimen using ranibizumab for neovascular age-related macular degeneration (AM…
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD [Phase 1, Phase 2]
Phase 1/2 clinical trial update for PAN-90806 eye drops in neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection [Phase 2]
Phase 2 clinical trial evaluating a fixed combination intravitreal injection targeting anti-angiopoietin 2 and anti-VEGF for neovascular age…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Post Intravitreal Injection Topical NSAID vs. Patching [Phase 4]
A Phase 4 trial update comparing post-intravitreal injection topical NSAID versus patching for neovascular age-related macular degeneration …
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD [Phase 4]
Phase 4 trial comparing ranibizumab on an as-needed basis to aflibercept every two months for maintaining retinal thickness stability in neo…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD [Phase 4]
Phase 4 trial evaluating safety and efficacy of switching from aflibercept to ranibizumab in patients with neovascular age-related macular d…
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Intense Treatment Regimen With Intravitreal Aflibercept Injection [Phase 1, Phase 2]
Phase 1/2 trial evaluating an intense intravitreal aflibercept treatment regimen for neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 trial update evaluating adjuvant anti-mineralocorticoid-receptor treatment for anti-VEGF refractory neovascular age-related macular …
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab [Phase 4]
Phase 4 trial update evaluating intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizuma…
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
This completed clinical trial reports real-world outcomes of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration…
-
CLINICAL_TRIALS trial_result · 2018-05-09Clinical Trial Update: Study of DS-7080a for the Treatment of Macular Degeneration [Phase 1]
A Phase 1 clinical trial evaluating DS-7080a for neovascular age-related macular degeneration and diabetic macular edema has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept [Phase 4]
Phase 4 clinical trial update evaluating a two-week retreatment interval for neovascular age-related macular degeneration that is refractory…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration [Phase 4]
This is a Phase 4 clinical trial evaluating fixed monthly dosing of ranibizumab for neovascular age-related macular degeneration. The study …
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Neovascular Age-related Macular Degeneration
Clinical trial investigating neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]
Phase 1 study evaluating multiple intravitreal injections of TK001 for neovascular age-related macular degeneration.